ChemoCentryx competitors

ChemoCentryx Competitors include Biogen, MyoKardia, Athersys and Reata Pharmaceuticals.
Add company...
ChemoCentryx
ChemoCentryx develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Founding Date
Founding Date
1997
Founding Date
1978
Founding Date
2012
Founding Date
1995
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Mountain View, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
Irving, US HQ
Employees
Employees
666% increase
Employees
7,300
Employees
1024% increase
Employees
6610% increase
Employees
75
Valuation ($)
Valuation ($)
506.3 m
Valuation ($)
65.5 b
Valuation ($)
2.3 b
Valuation ($)
265.1 m
Valuation ($)
N/A
Facebook likes
Facebook likes
N/A
Facebook likes
3.1 k
Facebook likes
N/A
Facebook likes
475
Facebook likes
184
Twitter followers
Twitter followers
N/A
Twitter followers
19.4 k
Twitter followers
387
Twitter followers
953
Twitter followers
418

Financial

Revenue (est.)
Revenue (est.)
$82.5m (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
N/A
Net income
Net income
$17.9m (FY, 2017)
Net income
$3.7b (FY, 2016)
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($47.7m) (FY, 2017)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Patents Issued
240 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 300m
For sources of this data, please see the company profileDownload Excel

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,300

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
66↑ 10% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Reata Pharmaceuticals
HQ
Irving, US
Employees
75

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company